CTLA4 and neoplasm: Disappointingly, the anti-CTLA-4 treatment’s effects on Treg cells remain inconclusive: While a reduction in tumour-infiltrating Tregs has been observed in some melanoma patients [15], other studies on melanoma, prostate and bladder tumours have reported no such depletion [16].